Importance The combination of immune checkpoint inhibitors with antiangiogenic agents
has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC) …

Background and Aims Regardless of great progress in early detection of hepatocellular
carcinoma (HCC), unresectable HCC (uHCC) still accounts for the majority of newly …

Background Hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin, and
oxaliplatin (FOLFOX), lenvatinib and programmed death receptor-1 signaling inhibitors …

Introduction Currently, conventional treatments of hepatocellular carcinoma (HCC) are not
selective enough for tumor tissue and lead to multidrug resistance and drug toxicity …

Hepatocellular carcinoma (HCC) is the second most lethal cancer and a leading cause of
cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) significantly …

Simple Summary Hepatocellular carcinoma (HCC) is the fifth most common cancer
worldwide and the second most common oncological reason for death. Liver resection and …

Hepatocellular carcinoma (HCC) is a major public health problem worldwide for which the
incidence and mortality are similar, pointing to the lack of effective treatment options …

Immune-oncology based regimens have shown efficacy in advanced hepatocellular
carcinoma and have been implemented as standard of care as first line therapy. Their …

Simple Summary Decrease of skeletal muscle mass index during atezolizumab plus
bevacizumab therapy was significantly associated with poor progression-free survival in …

Simple Summary Hepatocellular cancer is the most common type of primary liver cancer. It is
the third leading cause of cancer-related deaths worldwide and its incidence is increasing:> …